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Introduction
An imbalance between increased oxidative agents and antioxidant defense mechanisms is known as oxidative stress, which plays a critical role in the pathogenesis of multiple disorders, especially chronic respiratory disease like asthma, COPD, respiratory infections and lung cancer [1] . There are various external and internal factors, which can increase the severity of respiratory diseases (Figure 1) .
Studies involving asthmatics have demonstrated increased levels of reactive oxygen species (ROS) [2] and reactive nitrogen intermediates (RNI). These primarily include superoxide anions (O 2 -), hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals (OH). The major external sources of oxidative stress in asthma include air pollution, pollens, cigarette smoke and the influx of inflammatory cells into airways post allergen exposure. Whereas, internal factors include mitochondrial dysfunction and metabolic factors such as obesity/metabolic syndrome [2, 3] . In addition, asthma patients also have depleted antioxidant defenses, including superoxide dismutase, glutathioneand catalase .An increase in the levels of oxidative stress, either exogenous (smoking, air pollution etc.) or endogenous (generated by immune cells such as macrophages, neutrophils and eosinophils) is linked to more severe asthma [4] . Whilst NADPH oxidase-dependent complex and the cytosolic xanthine oxidase system is involved in the generation of ROS, the interaction of nitrite and myeloperoxidase or eosinophil peroxidase-
derived ROS results in RNI burden [4, 5] . The crucial triggers of asthma exacerbations include respiratory infections, environmental pollutants and certain drugs (e.g., aspirin) [6] . These activate differential inflammatory profiles and in turn, differential oxidative burden during exacerbations [7] . Moreover, increased levels of oxidative stress markers (plasma lipid peroxides) have been reported in asthma patients experiencing exacerbations [8] .
Low levels of oxidative stress initiate the release of antioxidant and anti-inflammatory genes via the activation of nuclear erythroid 2 p45-related factor 2 (Nrf2). In nucleus, Nrf2 binds to and activates antioxidant response element (ARE) leadingupregulation of genes encoding antioxidant-detoxifying proteins, including antioxidants (GPx), thiol metabolism-associated detoxifying enzymes (GSTs) and stress-response genes (HO-1) [9] . Evidently, Nrf2 seems to be protective against cigarette smoke-induced COPD, as Nrf2-deficient mice exposed to cigarette smoke exhibited greater bronchoalveolar inflammation, enhanced alveolar expression of 8-oxo-7,8-dihydro-2'-deoxyguanosine, increased apoptosis of endothelial and type II epithelial cells and most importantly, greater degree of emphysema when compared to control mice [10] . However, high intensities of oxidative stress trigger the activation of pro-inflammatory intracellular signaling leading to the expression of inflammatory cytokines, chemokines and adhesion molecules [11] resulting in increased airway inflammation and airway hyper-responsiveness.
Although glucocorticosteroids remain the mainstay therapy for the management of asthma, they are not adequate to control oxidative stress-induced airway inflammation due to their ability to interfere with the expression of anti-inflammatory genes as well as antioxidant enzymes [12] .
Hence, there is an urgent need to develop new strategies targeting oxidative stress to control or prevent airway inflammation. One potential approach could be the use of nanotechnology to improve antioxidant activity and lung function [13, 14] .
COPD is a multi-factorial disease that is primarily caused by the external factors such as, cigarette smoking and/or exposures to biomass smoke, air pollution and a variety of occupational exposures to chemical dust and fumes. All these risk factors are also frequently implicated in the increases in the oxidative burden and ROS/RNI in the lungs, as well as systemically [15] . For example, airway smooth muscle cells from COPD patients exhibited increased ROS levels compared to healthy individuals [16] . Likewise, the neutrophils harvested from the peripheral blood of COPD patients have been shown to produce more ROS compared to healthy individuals [17] . Increased levels of ROS can then initiate myriad of biochemical reactions, leading to damaged cellular components (proteins, lipids, and nucleic acids). Moreover, ROS also initiates inflammatory cascades via multiple mechanisms, such as protein kinase pathways, transcription factors, and genomic expression of pro-inflammatory regulators. All these factors result into an 'over-activated' immune system. Notably, the higher oxidative burden may lead to significant reductions in the VEGF levels in the lungs, which has been associated with the development of emphysema [17] . Inhalation of air pollutants results in the induction of oxidative stress in the lungs. For instance, inhalation of carbon particles present in air pollution, are retained by the lung tissues and induces oxidative stress [18] . Moreover, exposure to particulate matter from biomass/fossil fuels depletes anti-oxidants in cultured cells [19] . Occupational exposure (such as exposure to welding fumes) has been linked to significantly increased oxidative burden in the lung [20] .
Even though there arevarious options available for the treatment of COPD like PDE4 inhibitors, Respiratory infections, especially with Mycobacterium tuberculosis results in increased oxidative burden and inflammation in the lungs [21] . In addition, tuberculosis is also linked to increased risk of developing COPD [22] . Similarly, pulmonary infection with Streptococcus pneumoniae (common bacterial pathogen in CRDs) also induces oxidative stress that is depended on the pneumococcal auo lysin LytA, and independent of bacterial-derived H 2 O 2 and pneumolysin [23] .
Non-typeable Haemophilus influenzae (NTHi), also a major bacterial pathogen in CRDs, has been shown to induce ROS formation in human-derived primary cell lines (alveolar macrophages, human-lung fibroblast, and epithelial cell lines and blood-derived neutrophils) [24] . Moreover, mice infected with NTHi showed overproduction of oxidant, 3-nitrotyrosine (3-NT) in the lungs [24] . Furthermore, respiratory viral infections also affect redox homeostasis, which has been reviewed by Khomich et.al . [25] .
Lung cancer is the leading cause of death amongst all cancers especially in men all over the world [26] . Lung cancer can be classified as Non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC contributes to 85% of all the lung cancers [27] . The causes of lung cancer are attributed to smoking, inhalation of polluted air, noxious gases like ozone (O3), sulphur dioxide (SO2), nitrogen dioxide (NO2) and micro-organisms. Cigarette smoke accounts for 90% of lung cancer deaths [28] . It has carcinogens including nitrosamines, acrolein, and [29] . It also activates oncogenes such as c-jun, c-myc and c-fos, further induces over-expression of c-jun has been reported to conciliate growth factors for NSCLC [30] .
ROS/RNI also oxidizes protein and lipid moieties by carbonyl groups introduction in amino acids, the formation of protein-centered alkyls, malondialdehyde production etc. which eventually brings about the loss of histidine residues, oxidative scission, elevates mutagenesis and genotoxic products. Furthermore, these interact with DNA and modify polymerases, repair enzymes causing DNA-damage [31] . The most common DNA modification is 8-OH-G and is found to be 10 folds elevated in the urine of smokers [32] . In situations of inflammation in lungs, matrix metalloproteins (MMPs) interacts with growth factor, cytokines, chemokines, cell adhesion factors, apoptotic ligands, and angiogenic factors but over expression of MMPs induces tumor progression and metastasis [33] . During lung cancer, p53 is mutated causing defective apoptosis. p53 intervenes mitochondrial apoptotic signal by up-regulation of ROS [30] . The PIG3 protein responsible for oxidation-reduction, which is over-expressed in the tumor, thus fails to initiate apoptosis [34] . However, anti-oxidant therapy would contribute to balance oxidant levels in the body such as Thioredoxin (MOL-294) has been used against lung cancer, dietary supplements (Ascorbic acid, Vitamin E, β-carotene, Selenium etc.) reduce oxidative stress to some extent [35] . MMPs are an important component of the inflammatory cascade in lungs [33] , therefore nano-formulation based targeted drug delivery or gene therapy has the potential to control disease progression and provide us with a better understanding.
A variety of anti-oxidant therapies have been proposed for CRDs [36] , however, their targeted 
Microparticles
During the past decade, more attention has been given to the development of micro-particulate drug delivery carriers as these systems have better delivery of therapeutics to disease sites,particularly in treating pulmonary diseases [37, 38] . Particle size plays an important role in the delivery of drugs to the target site without affecting the non-target sites. It has been reported that the particle <0.5 µm cannot be retained in the airway for a prolonged time period due to the easy exhalation of such particles. On the other side particles with >10 µm diameter is suitable for deposition in the oropharynx. The microparticle in 1-5 µm size range is considered asanideal to achieve efficacious pulmonary deposition [39, 40] .
Amore et al. described alginate and chitosan-basedmucoadhesive solid lipid microparticles (SLMs) for the effective delivery of fluticasone propionate to treat chronic obstructive pulmonary diseases (COPDs). The developed SLMs were more effective in controlling oxidative stress-induced lung inflammation including ERK1/2 pathway activation and cigarette smoke extract-inducedsurvivin expression [39] . Lymphocyte-derivedmicroparticles (LMPs) stimulate oxidative stress in endothelial cells [41] . Qiuet al. (2014) identified that LMPs cause apoptosis of alveolar epithelial and bronchial cells by the activation of p38 mitogen-activated protein kinase signaling with an increase in cellular oxidative stress and arachidonic acid production [42] .
The first report on the expression of lung vascular endothelial growth factor in benzo(a)pyrenefed mouse model ofa lungtumour was published by Bandi and co-workers. PLGA microparticles released budesonide in a sustained manner for over 21 days. Microparticles have also showed potential of inhibiting the angiogenic factors in lung cancer on local delivery with a sustained release in benzo(a)pyrene-fed mice. This inhibtion resulting is attributed to the reduced malondialdehyde accumulation, glutathione depletion, vascular leakage, and vascular endothelial growth factor and c-myc expression.Inhibition of oxidative stress by the developed microparticles is especially beneficial in treating tumours [43] .
In a study, Yooet al. fabricated porous poly(lactide-co-glycolide) microparticles by water-in-oilin-water multi-emulsion method for effective pulmonary delivery of anthocyanin. Ammonium to deliver the microemulsion. The delivery of microemulsion from the nebulizer was controlled by the viscosity, particle sizeand aerodynamic particle size distribution. The aerodynamic particle size distributions produced by microemulsions using a jet nebuliser showed these to be promising results [51] .
Effective pulmonary delivery of atorvastatin from solid self-microemulsifying drug delivery system (S-SMEDDS) has been reported. The attempt for prepare microemulsion (ME) was firstly done using isopropyl myristate (IPM). The microemulsion was examined for difference was observed in mortality between tested groups [54] .
The applicability of etoposide, coix seed oil, and ginsenoside Rh2 containing microemulsion (ECGME) in lung cancer treatment has been validated and the mechanism underlying the enhanced antitumor efficacy has been explored. Ginsenoside Rh2 (G-Rh2) (3% w/w) was selected as optimum concentration to formulate microemulsion with small particle and high drug 
Microspheres
Microspheres are small and spherical particles with 1-1000 µm diameters [57] . 
Nanoparticles
These are the particles having a size range of 1-100nm and are the new approach for targeted delivery of the drugs [62] . Nanoparticles due to its small size have a tendency to behave as vessels for drugs, which in turn can reach any region of the humanbody [63] . The Intracellular cell adhesion molecule-1 (ICAM-1) and platelet endothelial cell adhesion molecule (PECAM) receptors present over the endothelial cells of pulmonary airways are targeted by these nanoparticles. Therefore, these can be used as carriers for NADPH oxidase (NOX) inhibitors, superoxide dismutase (SOD) and catalase in order to prevent oxidative stress in the respiratory 
Liposomes
Liposomes are the drug delivery system suitable for encapsulation of both hydrophilic and lipophilic drugs. Liposomes are attracted towards pulmonary delivery, following inhalation local drug effect is observed in the lungs with prolonged duration of action [67, 68] . Liposomal constituents phospholipids, cholesterol used in liposomes preparation are typically analogous to pulmonary surfactants in mammals [69, 70] . Many reports suggest liposomal constituents are found to compatible with alveolar macrophages, hydrogenated soy phosphatidylcholine (HSPC) and soy phosphatidylcholine (SPC) liposome exposure for prolonged nebulization (concentrations up to 150mg/mL) has no effect on the lungs of sheep. Liposomes found to be safe for inhalation in studies performed on human volunteers. Studies reveal liposomes are suitable for delivery of genes, antimicrobial agents and antidiabetic drugs [71] . (Figure 3 ).
Dendrimers
These are the branched systems containing a center area surrounded by star-shaped branches.
Various ligands could be attached at the surface for targeted release [75] . Esumi and co-workers Gold-PAMAM dendrimers were found to have more antioxidant activity than that of Gold-PPI dendrimers. When their activity was compared with ascorbic acid, the rate constant of Gold-PAMAM dendrimers was 85 times more than ascorbic acid. Thus, these have the potential of being used as a drug delivery system for targeting oxidative stress [76] . 
Lipid Nanocarriers:
Lipid-basednanocarriers are the drug delivery system widely used for lipophilic drug delivery.
Solid lipid nanocarriers (SLN), nanostructured lipid-based nanocarriers (NLC), liposomes are widely used nanocarriers in drug delivery. Lipid-based nanocarriers have several advantages in comparison to polymeric nanocarriers, lipid used in nanocarriers are non-toxic, free from organic solvents, exhibit good tolerability in air-ways and lipids used are of biodegradable [79] .
The nanosize of the lipid particles are easily aerosolized, they exhibit adhesion, accumulation, and retention in the lungs as well as prolong the drug release. These are ideal properties of the lipid nanocarriers make advantage in case of pulmonary drug delivery [37] . Lipid nanocarriers are more prone to adsorption on to the epithelium which helps to escape from mucociliary transport [80] .
Solid Lipid Nanocarriers:
Solid lipid nanocarriers are next-generation lipid nanocarriers of emulsion-based formulations where liquid oil is replaced with solid lipid. Solidnanocarriersprotect encapsulated drug, provide controlled release of the drug, with enhanced physical stability. Large-scale batches can be formulated in case of SLN using high shear homogenizer Solid lipid nanocarriers can overcome the limitations of liposomal drug delivery systems [37] . Liposomes cannot withstand the shear force exerted by nebulizer, physical stress gets applied on to the liposomal bilayer when aqueous dispersion is converted into the respirable aerosol formulation. This leads to loss of originally entrapped drug, this can be overcome by SLN based formulations [81] . 
Nanostructured Lipid Carriers:
Solid lipid nanocarriers exhibit limitations such as low potential drug loading and on storage,low ordered lipid modification is transformed to highly ordered β-modification. This leads to few imperfections in by perfect crystal lattice which leads to drug expulsion on storage.
Nanostructured lipid carriers are next generation to SLN in which solid lipid is mixed with liquid lipid at the ratio of 70:30 to 99.9:0.1. By the addition of the liquid lipid to the solid lipid matrix, it maintains lipid in a less ordered form which improves drug loading and stability of nanocarriers (decrease drug expulsion) [86] . vitro studies revealed there was no effect on cell viability. The in-vitro study was performed to check the effect of mucus on nanocarriers by application of artificial mucus layer, which revealed the mucus layer has no effect on SLNs [87] . was burst release of drug from the optimized formulation. Using jet stream and an ultrasonic nebulizer there was no effect on size and entrapment of nanocarriers [89] .
Patlolla and co-workers developed NLC of celecoxib by high-pressure homogenization. The particle size of the optimized formulation was 217±20 nm and >90 % entrapment. Fine particle fraction and median mass aerodynamic diameter were found to be 75.6+/-4.6 and 1.6+/-0.13µ in in-vitro aerosolization studies. In-vivo studies were performed in Balb/c mice, celecoxib NLC formulations showed 4 fold increase in AUC(t)/D in lung tissue compared to celecoxib solution.
The systemic clearance of celecoxib solution was 20.03 liter/hour were as celecoxib NLC clearance was 0.93 liters/hour. The study reveals improved bioavailability with minimal dosing interval [83] .
Miscellaneous

Mucoadhesive drug delivery system
Mucoadhesive drug delivery is mediated by the interaction between the mucus layer over the mucosal epithelial, mucin moieties and polymer/co-polymer with increased dosage residence time to the site of absorption [90] . This system is beneficial over other srug delivery systems are bound to mucus. Therefore, mucociliary clearance forces play role in particle disintegration, thus such a combination can be utilized for pulmonary gene therapy [104, 105] .
Transdermal patches:
The largest organ in the human body by mass is skin with a surface area of 16.1-21.5 sq. ft.
transdermal patches (TPs) has various advantages over conventional drug delivery such as a potential alternative to hypodermic injection and oral drug delivery systems that can also be used for drugs which undergo rapid first-pass metabolism with better patient compliance [106] . 
